[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-二羟基-10,13-二甲基-3-氧代-2,6,7,8,9,11,12,14,15,16-十氢-1H-环戊二烯并[a]菲-17-基]-2-氧代乙基]己酸酯 | 3593-96-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-二羟基-10,13-二甲基-3-氧代-2,6,7,8,9,11,12,14,15,16-十氢-1H-环戊二烯并[a]菲-17-基]-2-氧代乙基]己酸酯
• 中文别名: 己酸氢化可的松
• 英文名称: 21-hexanoyloxy-11β,17α-dihydroxypregn-4-en-3,20-dione
• 英文别名: hydrocortisone hexanoate；Hydrocortison capronat；Hydrocortisone caproate；[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] hexanoate
• CAS: 3593-96-2
• 化学式: C₂₇H₄₀O₆
• 分子量: 460.611
• InChiKey: XZSVYVIYKBHVMV-FOMYWIRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  氢化可的松 、 己酸甲酯 在 Candida antarctica lipase B 作用下， 以 甲苯 为溶剂， 以90%的产率得到[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-二羟基-10,13-二甲基-3-氧代-2,6,7,8,9,11,12,14,15,16-十氢-1H-环戊二烯并[a]菲-17-基]-2-氧代乙基]己酸酯
  参考文献：
  名称：

  Lipase-catalyzed regioselective preparation of fatty acid esters of hydrocortisone

  摘要：

  A series of fatty acid derivatives of hydrocortisone has been prepared by an enzymatic methodology. Nine 21-monoacyl products and one 3,11,17-triacetyl derivative, nine of them novel compounds, were obtained in a highly regioselective way through lipase-catalyzed esterification, transesterification and alcoholysis reactions. The influence of various reaction parameters Such as acylating agent: substrate ratio, enzyme: substrate ratio. solvent, temperature and nature of acylating agent and alcohol was evaluated. Among the tested lipases. Candida antarctica lipase appeared to be the most appropriate and showed a high efficient behavior especially in a one-pot transesterification. The advantages presented by this methodology, such as mild reaction conditions and low environmental impact, make the biocatalysis a convenient way to prepare acyl derivatives of hydrocortisone. These lipophilic compounds are potential products in the pharmaceutical industry. (C) 2009 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2009.07.010

文献信息

• Use of tocopherol ascorbic adic phosphates for hemorrhoidal diseases
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP0661053A1

  公开（公告）日：1995-07-05

  A therapeutic agent for hemorrhoidal diseases, comprising, as an active ingredient, a diester phosphate compound of the formula (I) wherein R₁ and R₂ are the same or different and each is a hydrogen atom or a methyl, or a pharmacologically acceptable salt thereof, and a method for treating hemorrhoidal diseases, comprising administering a pharmaceutically effective amount of said diester phosphate compound or a pharmacologically acceptable salt thereof.

  一种痔疮疾病治疗剂，其活性成分包括式 (I) 的磷酸二酯化合物 其中 R₁ 和 R₂ 相同或不同，且各自为氢原子或甲基，或其药理学上可接受的盐，以及治疗痔疮疾病的方法，包括施用药学上有效量的所述磷酸二酯化合物或其药理学上可接受的盐。
• Ophthalmic composition
  申请人：Menicon Co., Ltd.

  公开号：EP1308500A1

  公开（公告）日：2003-05-07

  An ophthalmic composition which contains a component A consisting of at least one member selected from the group consisting of polyoxyalkylene block copolymers and their derivatives, and a component B consisting of at least one member selected from the group consisting of caproic acid and its derivatives.

  一种眼科组合物，其中包含至少一种由聚氧亚烷基嵌段共聚物及其衍生物组成的成分 A 和至少一种由己酸及其衍生物组成的成分 B。
• Antifungal compositions comprising Sertaconazole and either Hydrocortisone or an antibacterial agent
  申请人：FERRER INTERNACIONAL, S.A.

  公开号：EP1698336A1

  公开（公告）日：2006-09-06

  Pharmaceutical compositions useful for treating dermal diseases caused by fungi and yeasts with inflammation and/or associated with a bacterial infection. Such compositions contain a therapeutically effective amount of Sertaconazole, or a pharmaceutically acceptable salt, solvate, isomer thereof or mixtures thereof; and a therapeutically effective amount of at least one compound selected from the group consisting of Hydrocortisone, a pharmaceutically acceptable ester of Hydrocortisone, an antibacterial agent or mixtures thereof.

  用于治疗真菌和酵母菌引起的皮肤疾病、炎症和/或与细菌感染有关的疾病的药物组合物。此类组合物含有治疗有效量的舍他康唑或其药学上可接受的盐、溶解物、异构体或其混合物；以及治疗有效量的至少一种选自氢可的松、氢可的松药学上可接受的酯、抗菌剂或其混合物的化合物。
• ANTIFUNGAL COMPOSITIONS COMPRISING SERTACONAZOL AND HYDROCORTISONE AND/OR AN ANTIBACTERIAL QUINOLONE COMPOUND
  申请人：FERRER INTERNACIONAL, S.A.

  公开号：EP1858510A1

  公开（公告）日：2007-11-28
• Antifungal Compositions
  申请人：Palacin Celia

  公开号：US20080166398A1

  公开（公告）日：2008-07-10

  Pharmaceutical compositions useful for treating dermal diseases caused by fungi and yeasts with inflammation and/or associated with a bacterial infection. Such compositions contain a therapeutically effective amount of sertaconazole, or a pharmaceutically acceptable salt, solvate, isomer thereof or mixtures thereof; and a therapeutically effective amount of at least one compound selected from the group consisting of hydrocortisone, a pharmaceutically acceptable ester of hydrocortisone, an antibacterial quinolone compound, and mixtures thereof.